Compounders may cut expenses by buying cheaper powders, not having them tested, etc. then use them to compound. This can be a public health risk in that the compounded product may not be the potency it is suppose to be. How can the FDA and state boards of pharmacy address this problem when they barely have enough resources to do what they are doing now to inspect compounders?
No comments:
Post a Comment